Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Significant Increase in <i>Clostridioides difficile</i> Mortality During the COVID-19 Pandemic: A Nationwide Study.

Gastro hep advances·2026
Same author

The prevalence of abdominal computed tomography imaging findings in patients with inflammatory bowel disease who present to the emergency department: a systematic review and meta-analysis.

Inflammatory bowel diseases·2026
Same author

Increased failure of budesonide MMX for ulcerative colitis during the COVID-19 pandemic: a population-based study.

Therapeutic advances in gastroenterology·2026
Same author

Letter: From Safety to Precision-Optimising the Use of GLP-1 Receptor Agonists in Gastroenterology.

Alimentary pharmacology & therapeutics·2026
Same author

Models of outpatient care delivery in inflammatory bowel disease: a scoping review.

Journal of the Canadian Association of Gastroenterology·2025
Same author

The Risk of Relapse Associated With Discontinuation of 5-Aminosalicylates in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.

Inflammatory bowel diseases·2025

Related Experiment Video

Updated: Jun 18, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Managing the risks of IBD therapy.

Cynthia H Seow1, Shanika de Silva, Gilaad G Kaplan

  • 1University of Calgary, TRW Building, Room 6D18, Calgary, Canada. cseow@ucalgary.ca

Current Gastroenterology Reports
|November 12, 2009
PubMed
Summary

Effective inflammatory bowel disease (IBD) management balances treatment benefits against risks to improve quality of life. Patient education and physician awareness are key for risk mitigation and optimal care strategies in IBD.

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Related Experiment Videos

Last Updated: Jun 18, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Area of Science:

  • Gastroenterology
  • Immunology
  • Clinical Medicine

Background:

  • Inflammatory bowel disease (IBD) management requires balancing therapeutic benefits with potential risks.
  • Risks include medication intolerance and severe complications from immunosuppression, such as sepsis.
  • Optimizing quality of life is a primary goal alongside disease remission.

Purpose of the Study:

  • To emphasize the importance of the benefit-to-risk assessment in IBD patient care.
  • To highlight the role of physician awareness and patient education in managing IBD.
  • To underscore the need for regular reassessment of therapy efficacy and risk.

Main Methods:

  • This is a conceptual overview, not a research study.
  • It synthesizes current understanding of IBD management principles.
  • Focuses on risk-benefit analysis and patient-clinician communication.

Main Results:

  • Optimal IBD management necessitates a proactive approach to risk identification and mitigation.
  • Early detection and appropriate management plans, including primary prevention, are crucial.
  • Continuous evaluation of treatment effectiveness is vital for successful long-term care.

Conclusions:

  • Successful IBD management hinges on a comprehensive strategy that includes symptom control, risk minimization, and quality of life enhancement.
  • Open communication between patients and clinicians is essential for achieving therapeutic goals and managing potential risks.
  • Proactive risk management and regular therapy reassessment are integral to optimal IBD patient outcomes.